IP Library › Granted Patent US 8,895,756
Granted Patent B2
US 8,895,756 · App. 13/719,409 · Granted Nov 25, 2014

Bendamustine pharmaceutical compositions

Inventors: Jason Edward Brittain (El Cajon, CA); Joe Craig Franklin (Tulsa, OK)
Assignee: Cephalon, Inc.
A61K9/19A61K9/0019A61K31/4184A61K47/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,895,756
App. No.
13/719,409
Granted
Nov 25, 2014
Kind
B2
Abstract

The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.

Claims (4)

1. A vial containing a reconstituted solution of bendamustine hydrochloride and mannitol in sterile water for injection, wherein the ratio by weight of bendamustine hydrochloride to mannitol in the vial is 15:25.5, and wherein the bendamustine hydrochloride is present in the vial at a concentration of 100 mg per 20 mL.

2. The vial of claim 1 , wherein the vial contains 25 mg of bendamustine hydrochloride.

3. The vial of claim 1 , wherein the vial contains 100 mg of bendamustine hydrochloride.

4. A 20 mL vial containing 100 mg of bendamustine hydrochloride and 170 mg of mannitol reconstituted in sterile water for injection.

Assignments (1)
CHANGE OF NAME Recorded Jul 26, 2022
From: CEPHALON, INC.
To: CEPHALON LLC
Reel/Frame 060921/0078 →
Continuity (4)
Continuation 13654898 · Oct 18, 2012
Continuation 11330868 · Jan 12, 2006
Provisional Application 60644354 · Jan 14, 2005
Related Publication 20130131131A1 · May 23, 2013